Prospective Staging Evaluation of Patients with Cutaneous T-Cell Lymphomas

Demonstration of a High Frequency of Extracutaneous Dissemination

  1. PAUL A. BUNN, Jr., M.D.;
  2. MARK S. HUBERMAN, M.D.;
  3. JACQUELINE WHANG-PENG, M.D.;
  4. GERALDINE P. SCHECHTER, M.D.;
  5. JOHN G. GUCCION, M.D.;
  6. MARY J. MATTHEWS, M.D.;
  7. ADI F. GAZDAR, M.D.;
  8. N. REED DUNNICK, M.D.;
  9. A. BETTY FISCHMANN, M.B.B.S.;
  10. DANIEL C. IHDE, M.D.;
  11. MARTIN H. COHEN, M.D.;
  12. BYRON FOSSIECK, M.D.; and
  13. JOHN D. MINNA, M.D.
  1. Washington, D.C.; and Bethesda, Maryland

    Abstract

    A prospective pretreatment staging evaluation was done on 49 consecutive patients with mycosis fungoides or the Sézary syndrome to study patterns of disease spread and prognostic factors. Routine staging procedures included complete blood count, blood chemistries, chest roentgenogram, lymphangiogram, radionuclide scans, bone marrow aspiration and biopsy, liver biopsy, and lymph node biopsy. Special evaluations included cytogenetic analysis, electron microscopy, and T-cell cytology. Extracutaneous lymphoma was documented by light microscopy in 51% of patients and by the three special procedures in 88%. Extracutaneous lymphoma was most frequent in blood and lymph nodes; 18% of patients had visceral involvement. Patients with generalized erythroderma had a higher frequency of extracutaneous disease than did patients with cutaneous plaques and tumors by both light microscopy and special studies. Survival was directly related to the type of skin involvement and the presence or absence of extracutaneous disease. Systemic dissemination of cutaneous T-cell lymphoma is frequent, generally asymptomatic, and develops early via the circulation. These findings may explain why cutaneous therapies are associated with a high frequency of relapse.

    Article and Author Information

    • ▸From the National Cancer Institute-Veterans Administration Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute and Veterans Administration Medical Center, Washington, D.C.; the Hematology and Dermatology Sections, Medical Service, and Electron Microscopy, Laboratory Service, Veterans Administration Medical Center, Washington, D.C.; the Departments of Medicine and Pathology, George Washington University School of Medicine, and the Department of Medicine, Georgetown University School of Medicine, Washington, D.C.; the Cytogenetic Oncology Section, Medicine Branch, National Cancer Institute, Bethesda, Maryland; and the Diagnostic Radiology Department, Clinical Center, National Institutes of Health, Bethesda.

    • ▸Requests for reprints should be addressed to Paul A. Bunn, Jr., M.D.; National Cancer Institute-Veterans Administration Medical Oncology Branch, Veterans Administration Medical Center, 50 Irving Street, N.W.; Washington, D.C. 20422.

    « Previous | Next Article »Table of Contents